Zacks: Analysts Expect Orgenesis Inc. (ORGS) Will Announce Earnings of -$0.22 Per Share

Wall Street brokerages forecast that Orgenesis Inc. (NYSE:ORGS) will report earnings of ($0.22) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Orgenesis’ earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.14). Orgenesis reported earnings per share of ($0.52) during the same quarter last year, which would suggest a positive year-over-year growth rate of 57.7%. The company is expected to issue its next quarterly earnings report on Monday, May 20th.

On average, analysts expect that Orgenesis will report full-year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.60) to ($0.45). For the next year, analysts anticipate that the firm will report earnings of ($0.17) per share. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Orgenesis.

Orgenesis (NYSE:ORGS) last announced its quarterly earnings data on Wednesday, February 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.18). The firm had revenue of $5.80 million during the quarter, compared to analysts’ expectations of $7.78 million.

Shares of Orgenesis stock traded up $0.08 during trading on Wednesday, hitting $4.50. 300 shares of the stock traded hands, compared to its average volume of 31,984. Orgenesis has a 52 week low of $3.87 and a 52 week high of $9.50.

Orgenesis Company Profile

Orgenesis Inc, a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. It operates through two segments, Contract Development and Manufacturing Organizations (CDMO) and Cellular Therapy (CT) Business.

Featured Article: Cash Flow Analysis in Stock Selection

Get a free copy of the Zacks research report on Orgenesis (ORGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.